These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 15906386)

  • 21. Is psychological stress in man associated with increased striatal dopamine levels?: A [11C]raclopride PET study.
    Montgomery AJ; Mehta MA; Grasby PM
    Synapse; 2006 Aug; 60(2):124-31. PubMed ID: 16715491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
    Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extrastriatal D2 and striatal D2 receptors in depressive illness: pilot PET studies using [11C]FLB 457 and [11C]raclopride.
    Montgomery AJ; Stokes P; Kitamura Y; Grasby PM
    J Affect Disord; 2007 Aug; 101(1-3):113-22. PubMed ID: 17197036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties.
    Prinssen EP; Kleven MS; Koek W
    Eur J Pharmacol; 1998 Sep; 356(2-3):189-92. PubMed ID: 9774248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
    Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system.
    Galineau L; Wilson AA; Garcia A; Houle S; Kapur S; Ginovart N
    Synapse; 2006 Aug; 60(2):172-83. PubMed ID: 16715499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute NMDA receptor antagonism induces biphasic striatal utilization of L-[beta-11C]DOPA: PET studies in the conscious monkey brain.
    Tsukada H; Harada N; Nishiyama S; Fukumoto D; Kakiuchi T
    Synapse; 2005 Aug; 57(2):116-9. PubMed ID: 15906382
    [No Abstract]   [Full Text] [Related]  

  • 29. Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography.
    Tiihonen J; Kuoppamäki M; Någren K; Bergman J; Eronen E; Syvälahti E; Hietala J
    Psychopharmacology (Berl); 1996 Aug; 126(4):277-80. PubMed ID: 8878342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice.
    Gomes FV; Del Bel EA; Guimarães FS
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():43-7. PubMed ID: 23791616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of striatal dopamine D2/D3 receptor binding potential with pain but not tactile sensitivity or placebo analgesia.
    Martikainen IK; Hagelberg N; Mansikka H; Hietala J; Någren K; Scheinin H; Pertovaara A
    Neurosci Lett; 2005 Mar; 376(3):149-53. PubMed ID: 15721212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ketamine does not decrease striatal dopamine D2 receptor binding in man.
    Aalto S; Hirvonen J; Kajander J; Scheinin H; Någren K; Vilkman H; Gustafsson L; Syvälahti E; Hietala J
    Psychopharmacology (Berl); 2002 Dec; 164(4):401-6. PubMed ID: 12457270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET.
    Linazasoro G; Obeso JA; Gómez JC; Martínez M; Antonini A; Leenders KL
    Clin Neuropharmacol; 1999; 22(5):277-80. PubMed ID: 10516878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The alpha 2-adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: role of serotonergic mechanisms.
    Invernizzi RW; Garavaglia C; Samanin R
    Neuropsychopharmacology; 2003 May; 28(5):872-9. PubMed ID: 12644843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. D2 receptor occupancy in conscious rat brain is not significantly distinguished with [3H]-MNPA, [3H]-(+)-PHNO, and [3H]-raclopride.
    Peng T; Zysk J; Dorff P; Elmore CS; Ström P; Malmquist J; Ding M; Tuke D; Werkheiser J; Widzowski D; Mrzljak L; Maier D
    Synapse; 2010 Aug; 64(8):624-33. PubMed ID: 20340171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
    McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
    Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of striatal dopamine release through 5-HT1 and 5-HT2 receptors.
    Ng NK; Lee HS; Wong PT
    J Neurosci Res; 1999 Mar; 55(5):600-7. PubMed ID: 10082082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease.
    van Oostrom JC; Maguire RP; Verschuuren-Bemelmans CC; Veenma-van der Duin L; Pruim J; Roos RA; Leenders KL
    Neurology; 2005 Sep; 65(6):941-3. PubMed ID: 16186542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
    Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
    J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.
    Dupre KB; Eskow KL; Barnum CJ; Bishop C
    Neuropharmacology; 2008 Dec; 55(8):1321-8. PubMed ID: 18824001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.